2
Registered trials
0
Recruiting
2
Unique sponsors
3
Unique IMPs
2
Commercial trials
Drug classes (ATC)
—
ATC code not specified
1
L
Oncology (ATC L)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Checkpoint inhibitor (PD-1)
1 substance
Phase II:
1
Phase I (First in Human):
1
Phase II
1 trial-
EndedOwlstone Medical Limited CommercialD5-ETHYL-BETA-D-GLUCURONIDE
Phase I (First in Human)
1 trial-
EndedAchilles Therapeutics UK Limited CommercialATL001; PEMBROLIZUMAB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Owlstone Medical Limited | Commercial | 1 | Phase II | 0 |
| Achilles Therapeutics UK Limited | Commercial | 1 | Phase I (First in Human) | 0 |
New trials by year
2021
1
2023
1